HCS - Ενδιαφέροντα άρθρα και links

Ενδιαφέροντα άρθρα και links

Άρθρα

1. P.M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P.K. Whelton and J. He, Global burden of hypertension: analysis of world-wide data, Lancet 2005; 365: 217–223

2. G. deSimone, R.B. Devereux, M. Chinali et al. and Strong Heart Study Investigators, Risk factors for arterial hypertension in adults with initial optimal blood pressure, Hypertension 2006; 47: 162–167

3. R.O. Halperin, H.D. Sesso, J. Ma, J.E. Buring, M.J. Stampfer and J.M. Gaziano, Dyslipidemia and risk of incident hypertension in men, Hypertension 2006;47:45–50

4. R.S. Vasan, M.G. Larson, E.P. Leip, W.B. Kannel and D. Levy, Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study, Lancet 2001; 358: 1682–1686.

5. S. Julius, S.D. Nesbitt and B.M. Egan et al., Feasibility of treating prehypertension with an angiotensin-receptor blocker, N Engl J Med 2006;354: 1–13.

6. H.O. Dickinson, J.M. Mason and D.J. Nicolson et al., Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials, J Hypertens 2006;24:215–233.

7. L.J. Appel, M.W. Brands, S.R. Daniels, N. Karanja, P.J. Elmer and F.M. Sacks, Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association, Hypertension 2006; 47:296–308

8. E. Dolan, A. Stanton and L. Thijs et al., Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin Outcome Study, Hypertension 2005; 46:156–161

9. H. Metoki, T. Ohkubo and M. Kikuya et al., Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama Study, Hypertension 2006; 47:149–154

10. B. Williams and P.S. Lacy, Blood pressure and outcomes in clinical trials, J Hypertens 2005; 23:487–488.

11. Y. Li, J.-G. Wang and E. Dolan et al., Ambulatory Arterial Stiffness Index derived from 24-hour ambulatory blood pressure monitoring, Hypertension 2006; 47:359–364

12. 18 E. Dolan, L. Thijs and Y. Li et al., Ambulatory Arterial Stiffness Index as a predictor of cardiovascular mortality in the Dublin Outcome Study, Hypertension 2006; 47: 365–370

13. S. Laurent, Surrogate measures of arterial stiffness: do they have additive predictive value or are they only surrogates of a surrogate?, Hypertension 2006; 47: 325–326.

14. B. Dahlof, P.S. Sever, N.R. Poulter et al. and ASCOT Investigators, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial, Lancet 2005; 366: 895–906

15. P.S. Sever, B. Dahlof, N.R. Poulter et al. and ASCOT Investigators, Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial, Lancet 2003; 361: 1149–1158

16. P.S. Sever, B. Dahlof, N.R. Poulter et al. and ASCOT Investigators, Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm, Diabetes Care 2005; 28: 1151–1157

17. N.R. Poulter, H. Wedel, B. Dahlof et al. and ASCOT Investigators, Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial–BloodPressure Lowering Arm (ASCOT-BPLA), Lancet 2005; 366: 907–914.

18. The CAFE Investigators, Differential impact of blood pressure–lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study, Circulation 2006; 113: 1213–1225.

19. Z. Dhakam, C.M. McEniery, Yasmin, J.R. Cockcroft, M.J. Brown and I.B. Wilkinson, Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity, Am J Hypertens 2006; 19: 214–219

20. A.M. Dart, C.D. Gatzka and B.A. Kingwell et al., Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives, Hypertension 2006; 47: 1–6.

21. J.T. Wright Jr., J.K. Dunn, J.A. Cutler et al. and ALLHAT Collaborative Research Group, Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril, JAMA 2005; 293: 1595–1608

22. P.K. Whelton, J. Barzilay, W.C. Cushman et al. and ALLHAT Collaborative Research Group, Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia, Arch Intern Med 2005; 165: 1401–1409

23. M. Mahboob-Rahman, S. Pressel, B.R. Davis et al. and ALLHAT Collaborative Research Group, Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic, Arch Intern Med 2005; 165: 936–946.

24. J.A. Cutler, Calcium-channel blockers for hypertension—uncertainty continues, N Engl J Med 1998; 338 (1998): 679–681.

25. F. Turnbull, B. Neal and C. Algert et al., Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials, Arch Intern Med 2005;165: 1410–1419.

26. J. Schrader, S. Luders, A. Kulschewski et al. and MOSES Study Group, Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES), Stroke 2005; 36: 1218–1226.

27. S. Stewart, C.L. Hart, D.J. Hole and J.J. McMurray, A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study, Am J Med 2002; 113:359–364.

28. H. Vidaillet, J.F. Granada and P.H. Chyou et al., A population-based study of mortality among patients with atrial fibrillation or flutter, Am J Med 2002;113: 365–370.

29. T.S. Tsang, G.W. Petty and M.E. Barnes et al., The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades, J Am Coll Cardiol 2003;42: 93–100.

30. K. Wachtell, M. Lehto and E. Gerdts et al., Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study, J Am Coll Cardiol 2005; 45: 712–719

31. K. Wachtell, B. Hornestam and M. Mika-Lehto et al., Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study, J Am Coll Cardiol 2005;45: 705–711.

32. R. Fogari, A. Mugellini and M. Destro et al., Losartan and prevention of atrial fibrillation recurrence in hypertensive patients, J Cardiovasc Pharmacol 2006; 47:46–50.

33. O.D. Pedersen, H. Bagger and L. Keber et al., Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction, Circulation 1999;100: 376–380

34. A.H. Madrid, M.G. Bueno and J.M. Rebollo et al., Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation A prospective and randomized study, Circulation 2002;106: 331–336.

35. E. Vermes, J.C. Tardif and M.G. Bourassa et al., Enalapril decreased the incidence of atrial fibrillation in patients with left ventricular dysfunction Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials, Circulation 2003; 107:2926–2931.

36. H. Nakashima, K. Kumagai and H. Urata et al., Angiotensin II antagonists prevents electrical remodeling in atrial fibrillation, Circulation 2000; 101: 2612–2617.

37. P.M. Kistler, N.C. Davidson and P. Sanders et al., Absence of acute effects of angiotensin II on atrial electrophysiology in humans, J Am Coll Cardiol 205; 45: 154–156.

38. K. Kumagai, H. Nakashima and H. Urata et al., Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation, J Am Coll Cardiol 2003; 41: 2197–2204

39. E. Gerdts, L. Oikarinen and V. Palmieri et al., Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy The Losartan Intervention for End point reduction in hypertension (LIFE) study, Hypertension 2002; 39:739–743.

40. R.B. Devereux, B. Dahlof and E. Gerdts et al., Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol The Losartan Intervention For End point reduction in Hypertension (LIFE) trial, Circulation 2004; 110: 1456–1462.

41. L.H. Lindholm, B. Carlberg and O. Samuelsson, Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis, Lancet 2005;366:1545–1553.

42. Blood Pressure Lowering Treatment Trialists’ Collaboration, Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials, Lancet 2003; 36: 1527–1545.

43. J.M. Mason, H.O. Dickinson, D.J. Nicolson, F. Campbell, G.A. Ford and B. Williams, The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension, J Hypertens 2005; 3:1777–1781.

Links

American College of Cardiology

American Heart Association

American Heart Association Journals

American Journal of Hypertension

American Society of Hypertension

British Hypertension Society

European Society of Cardiology

European Society of Hypertension

Hellenic Cardiological Society

Hellenic Heart Foundation

Hellenic Society of Hypertension